LU91398I2 - "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard - Google Patents

"La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard

Info

Publication number
LU91398I2
LU91398I2 LU91398C LU91398C LU91398I2 LU 91398 I2 LU91398 I2 LU 91398I2 LU 91398 C LU91398 C LU 91398C LU 91398 C LU91398 C LU 91398C LU 91398 I2 LU91398 I2 LU 91398I2
Authority
LU
Luxembourg
Prior art keywords
recombinant
protein
silgard
gardasil
human papillomavirus
Prior art date
Application number
LU91398C
Other languages
English (en)
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91398(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of LU91398I2 publication Critical patent/LU91398I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91398C 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard LU91398I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (fr) 1992-06-25 1993-06-24 Vaccin contre le papillomavirus

Publications (1)

Publication Number Publication Date
LU91398I2 true LU91398I2 (fr) 2008-02-14

Family

ID=25416951

Family Applications (8)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91397C LU91397I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
LU91393C LU91393I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
LU91398C LU91398I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Family Applications Before (5)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91397C LU91397I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
LU91393C LU91393I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Country Status (12)

Country Link
US (2) US20020068326A1 (fr)
EP (2) EP1835029A1 (fr)
AT (1) ATE380871T1 (fr)
AU (1) AU697743C (fr)
DE (9) DE122007000094I1 (fr)
DK (1) DK0647140T3 (fr)
ES (1) ES2294778T3 (fr)
FR (1) FR07C0073I2 (fr)
LU (8) LU91395I2 (fr)
NL (8) NL300316I1 (fr)
PT (1) PT647140E (fr)
WO (1) WO1994000152A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000085I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
BR9507657A (pt) * 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
JPH10506014A (ja) * 1994-09-22 1998-06-16 メルク エンド カンパニー インコーポレーテッド ヒトパピローマウイルス６ａ型をコードするＤＮＡ
DE122007000093I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
AU755679B2 (en) * 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1104442A1 (fr) 1998-07-13 2001-06-06 Loyola University Of Chicago Recepteur cellulaire du papillomavirus
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
WO2010079505A2 (fr) 2008-05-26 2010-07-15 Cadila Healthcare Limited Vaccin combine rougeole-papillome humain
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
WO2010112533A1 (fr) * 2009-04-03 2010-10-07 Deutsches Krebsforschungszentrum Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP3242135B1 (fr) 2010-04-08 2020-07-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
WO2013119856A1 (fr) 2012-02-07 2013-08-15 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2014066443A1 (fr) 2012-10-23 2014-05-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
CA3023271A1 (fr) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3078223A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procedes d'utilisation
WO2020243115A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procédé de séchage par atomisation d'une émulsion de vaccin et d'adjuvant
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
EP4583841A1 (fr) 2022-09-09 2025-07-16 Access to Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (fr) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharides et composés macromoléculaires contenant ces polysaccharides
AU650868B2 (en) * 1990-03-20 1994-07-07 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
DE122007000085I1 (de) * 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms

Also Published As

Publication number Publication date
DE122007000094I1 (de) 2008-03-27
DE122007000098I1 (de) 2008-03-27
NL300317I1 (nl) 2008-02-01
ES2294778T3 (es) 2008-04-01
DE69334192T2 (de) 2008-12-04
NL300315I2 (nl) 2008-03-03
DK0647140T3 (da) 2008-02-04
NL300321I1 (nl) 2008-03-03
FR07C0073I1 (fr) 2008-01-02
ATE380871T1 (de) 2007-12-15
NL300322I1 (nl) 2008-03-03
LU91399I2 (fr) 2008-02-14
FR07C0073I2 (fr) 2012-08-03
NL300319I1 (nl) 2008-03-03
LU91393I2 (fr) 2008-02-14
NL300318I2 (nl) 2008-03-03
DE122007000095I1 (de) 2008-03-27
EP0647140A1 (fr) 1995-04-12
DE122007000097I1 (de) 2008-03-27
LU91397I2 (fr) 2008-02-14
PT647140E (pt) 2007-12-27
NL300316I1 (nl) 2008-02-01
NL300320I1 (nl) 2008-03-03
AU1135295A (en) 1996-02-08
DE122007000101I1 (de) 2008-03-27
DE122007000100I1 (de) 2008-03-27
US20020068326A1 (en) 2002-06-06
NL300315I1 (nl) 2008-02-01
US8012679B1 (en) 2011-09-06
DE122007000099I1 (de) 2008-03-27
LU91396I2 (fr) 2008-02-14
WO1994000152A1 (fr) 1994-01-06
LU91395I2 (fr) 2008-02-14
AU697743B2 (en) 1998-10-15
DE69334192D1 (de) 2008-01-24
EP0647140A4 (fr) 1997-03-19
EP0647140B1 (fr) 2007-12-12
EP1835029A1 (fr) 2007-09-19
NL300318I1 (nl) 2008-02-01
DE122007000096I1 (de) 2008-03-27
LU91400I2 (fr) 2008-02-14
LU91394I2 (fr) 2008-02-14
AU697743C (en) 2007-06-14

Similar Documents

Publication Publication Date Title
LU91397I2 (fr) "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine